Table 3.
Estimated mean difference in 5-year change from baseline on composite Z score for the three intervention groups compared to the placebo group
| Groups | Estimated mean change from baseline (95% CI) | Estimated mean between-group difference in change from baseline (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusteda | ||||||
| vs. placebo | Raw P | Hochberg P | vs. placebo | Raw P | Hochberg P | ||
| 5-year ITT MAPT-PLUS analysis (n = 483) | |||||||
| Positive plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.2023 (-0.4824; 0.0778) | 0.2575 (-0.1004; 0.6154) | 0.1579 | 0.4737 | 0.2501 (-0.1071; 0.6073) | 0.1691 | 0.5074 |
| Omega 3 alone | -0.4255 (-0.6705; -0.1804) | 0.0343 (-0.2969; 0.3656) | 0.8385 | 0.8385 | -0.0288 (-0.3665; 0.3089) | 0.8666 | 0.8666 |
| Multidomain plus placebo | -0.5209 (-0.7967; -0.2451) | -0.0611 (-0.4157; 0.2935) | 0.7348 | 0.8385 | -0.1582 (-0.5153; 0.1988) | 0.3838 | 0.7676 |
| Placebo | -0.4598 (-0.6827; -0.2369) | - | - | - | - | - | - |
| Negative plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.2870 (-0.4388; -0.1351) | -0.0358 (-0.2674; 0.1959) | 0.7614 | 0.7614 | -0.0237 (-0.2569; 0.2095) | 0.8415 | 0.8415 |
| Omega 3 alone | -0.1524 (-0.3287; 0.0239) | 0.0988 (-0.1495; 0.3471) | 0.4339 | 0.7614 | 0.1008 (-0.1489; 0.3506) | 0.4271 | 0.8415 |
| Multidomain plus placebo | -0.3384 (-0.5079; -0.1690) | -0.0872 (-0.3307; 0.1563) | 0.4812 | 0.7614 | -0.1107 (-0.3563; 0.1348) | 0.3753 | 0.8415 |
| Placebo | -0.2512 (-0.4261; -0.0763) | - | - | - | - | - | - |
| 5-year per-protocol MAPT-PLUS analysis (n = 457) | |||||||
| Positive plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.1315 (-0.4197; 0.1567) | 0.3233 (-0.0453; 0.6919) | 0.0853 | 0.2560 | 0.3202 (-0.0475; 0.6880) | 0.0876 | 0.2628 |
| Omega 3 alone | -0.4254 (-0.6737; -0.1771) | 0.0293 (-0.3090; 0.3677) | 0.8645 | 0.8645 | -0.0423 (-0.3874; 0.3028) | 0.8095 | 0.8095 |
| Multidomain plus placebo | -0.5349 (-0.8177; -0.2522) | -0.0802 (-0.4445; 0.2842) | 0.6652 | 0.8645 | -0.1807 (-0.5482; 0.1868) | 0.3340 | 0.6679 |
| Placebo | -0.4548 (-0.6846; -0.2250) | - | - | - | - | - | - |
| Negative plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.2920 (-0.4524; -0.1315) | -0.0378 (-0.2773; 0.2016) | 0.7559 | 0.7559 | -0.0277 (-0.2686; 0.2132) | 0.8209 | 0.8209 |
| Omega 3 alone | -0.1613 (-0.3418; 0.0192) | 0.0929 (-0.1605; 0.3462) | 0.4710 | 0.7559 | 0.0825 (-0.1719; 0.3370) | 0.5234 | 0.8209 |
| Multidomain plus placebo | -0.3388 (-0.5183; -0.1593) | -0.0847 (-0.3373; 0.1679) | 0.5098 | 0.7559 | -0.1017 (-0.3570; 0.1536) | 0.4334 | 0.8209 |
| Placebo | -0.2541 (-0.4319; -0.0764) | - | - | - | - | - | - |
ITT Intention-to-treat, MAPT Multidomain Alzheimer Prevention Trial
aAnalysis adjusted for age, sex, level of education, APOE ε4 genotype, and clinical dementia rating global score